GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...

The significantly longer half-life of Flyrcado (109 minutes) allows for it to be manufactured at an offsite pharmacy and delivered as a ready-to-use unit dose. The approval was supported by data from ...

GE HealthCare GEHC recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emission ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration approved GE HealthCare's (GEHC.O), opens new tab diagnostic drug for use in detection of coronary artery disease, the company said on Friday.

GE Healthcare Technologies Inc. received U.S. FDA approval for its novel radiotracer, Flyrcado (flurpiridaz F-18), for use in the diagnosis of myocardial ischemia or infarction in patients with known ...

GE HealthCare Technologies, Inc. GEHC announced that it has received FDA approval for Flyrcado (flurpiridaz F 18), a breakthrough positron emission tomography myocardial perfusion imaging (PET MPI) ...

GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo.

Cleveland-based University Hospitals Harrington Heart & Vascular Institute has become the first site in Ohio to clinically administer Flyrcado for the detection of coronary artery disease and arterial ...

CVAUSA, the largest network of private cardiology groups in the U.S., plans to broadly adopt Flyrcado in line with its mission to deliver the highest quality cardiovascular care for patients. CVAUSA ...

(RTTNews) - GE HealthCare Technologies Inc. (GEHC) Monday announced a Distribution and Services Agreement (DSA) with CardioNavix, a part of the CDL Nuclear Technologies services group, for GE ...

The nation's largest network of private cardiology groups will broaden its adoption of GE HealthCare's PET scan radiotracer drug Flyrcado, helping move the Chicago-based medical equipment maker toward ...

GE HealthCare’s agreement with CardioNavix, a part of the CDL Nuclear Technologies services group, further broadens the reach of Flyrcado. Through their nearly 225 U.S. customers, CDL and CardioNavix ...